Skip to main content

Advertisement

SpringerLink
Log in

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer

  • SPECIAL ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Oligometastatic disease (OMD) defines a status of cancer that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While imaging diagnostic tools have considerably improved in recent years, unidentified micrometastases can still escape from current detection techniques allowing disease to progress. The variety of OMD scenarios are mainly defined by the number of metastases, the biological and molecular tumour profiles, and the timing of the development of metastases. Increasing knowledge has contributed to the earlier and improved detection of OMD, underlining the importance of an early disease control. Based on increasing detection rates of OMD in the current real clinical practice and the lack of standardized evidence-based guidelines to treat this cancer status, a board of experts from the Spanish Societies of Radiation Oncology (SEOR) and Medical Oncology (SEOM) organized a series of sessions to update the current state-of-the-art on OMD from a multidisciplinary perspective, and to discuss how results from clinical studies may translate into promising treatment options. This experts’ review series summarizes what is known and what it is pending clarification in the context of OMD in the scenarios of Non-Small Cell Lung Cancer and Breast Cancer (Part I), and Prostate Cancer and Colorectal Cancer (Part II), aiming to offer specialists a pragmatic framework that might contribute to the improved management of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and material

Not applicable.

References

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.

    Article  CAS  PubMed  Google Scholar 

  2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.

    Article  CAS  PubMed  Google Scholar 

  3. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66.

    Article  PubMed  Google Scholar 

  4. Olson RA, Jiang W, Liu MC, Bergman A, Schellenberg D, Mou B, et al. Population based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: preliminary results of the SABR-5 trial. Int J Radiat Oncol Biol Phys. 2021;111(3):S4.

    Article  Google Scholar 

  5. Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28.

    Article  PubMed  Google Scholar 

  7. Szturz P, Nevens D, Vermorken JB. Oligometastatic disease management: finding the sweet spot. Front Oncol. 2020;10(2872): 617793.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32(26):2902–12.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol. 2011;23(2):133–9.

    Article  PubMed  Google Scholar 

  10. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A Patterns Fail Anal Acta Oncol. 2009;48(4):578–83.

    CAS  Google Scholar 

  11. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.

    Article  PubMed  Google Scholar 

  12. de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25(2):467–71.

    Article  PubMed  Google Scholar 

  13. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.

    Article  PubMed  Google Scholar 

  14. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Perera M, Papa N, Christidis D, Wetherell D, Hofman M, Murphy D, et al. Effect of PSA on diagnostic yield of 68Ga-PSMA PET in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol Suppl. 2016;15(12): e1540.

    Article  Google Scholar 

  16. Mottet, N., Cornford, P., van den Bergh, R.C.N., Briers, E., UOMO), E.P.A.E.P.C.C.E., De Santis, M., et al., EAU Guidelines. https://uroweb.org/guidelines/2019. 2019.

  17. Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, et al. A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III). J Urol. 2019;201(4):682–92.

    Article  PubMed  Google Scholar 

  18. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–82.

    Article  CAS  PubMed  Google Scholar 

  19. Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). BMC Cancer. 2017;17(1):453.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich cancer registry. Eur Urol. 2014;66(3):602–3.

    Article  PubMed  Google Scholar 

  21. Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. 2016;69(5):788–94.

    Article  PubMed  Google Scholar 

  22. Leyh-Bannurah SR, Gazdovich S, Budaus L, Zaffuto E, Briganti A, Abdollah F, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72(1):118–24.

    Article  PubMed  Google Scholar 

  23. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835–42.

    Article  CAS  PubMed  Google Scholar 

  24. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410–8.

    Article  PubMed  Google Scholar 

  26. Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116:1520–5.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53.

    Article  CAS  PubMed  Google Scholar 

  28. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–9.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L, et al. Metastasis-directed therapy (SBRT) guided by PET-CT (18)F-CHOLINE versus PET-CT (68)Ga-PSMA in Castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer. 2021;19(3):230–6.

    Article  PubMed  Google Scholar 

  30. Prive BM, Peters SMB, Muselaers CHJ, van Oort IM, Janssen MJR, Sedelaar JPM, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. Clin Cancer Res. 2021;27(13):3595–601.

    Article  CAS  PubMed  Google Scholar 

  31. Gonzalez Del Alba A, Mendez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, et al. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol. 2021;23(5):969–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.

    Article  CAS  PubMed  Google Scholar 

  35. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.

    Article  CAS  PubMed  Google Scholar 

  36. Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992–2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana Gomes AJP, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.

    Article  CAS  PubMed  Google Scholar 

  38. Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana Gomes AJP, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–303.

    Article  CAS  PubMed  Google Scholar 

  39. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31.

    Article  CAS  PubMed  Google Scholar 

  40. Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, et al. Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol. 2019;76(6):719–28.

    Article  CAS  PubMed  Google Scholar 

  41. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022;25(2):274–82.

    Article  CAS  PubMed  Google Scholar 

  43. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Fizazi K, Carles Galceran J, Foulon S, Roubaud G, McDermott R, Fléchon A, et al. LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. Ann Oncol. 2021;32:S1299.

    Article  Google Scholar 

  45. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A. Consensus on management of castration-resistant prostate cancer on behalf of the urological tumours working group (URONCOR) of the Spanish society of radiation oncology. Clin Transl Oncol. 2019;21(4):420–32.

    Article  PubMed  Google Scholar 

  47. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, et al. Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. Eur Urol. 2022;82(1):115–41.

    Article  CAS  PubMed  Google Scholar 

  48. Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37(12):2631–7.

    Article  CAS  PubMed  Google Scholar 

  49. Yoshida S, Takahara T, Arita Y, Ishii C, Uchida Y, Nakagawa K, et al. Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor. Int J Radiat Oncol Biol Phys. 2019;105(2):376–81.

    Article  PubMed  Google Scholar 

  50. Conde-Moreno AJ, Lopez F, Hervas A, Morillo V, Mendez A, Puertas MDM, et al. Phase II trial of SBRT and androgen deprivation for oligometastases in prostate cancer. Int J Radiat Oncol Biol Phys. 2021;111(3):S59.

    Article  Google Scholar 

  51. Conde-Moreno AJ, Lopez F, Hervas A, Morillo V, Mendez A, Puertas MDM, et al. Phase II trial of SBRT and androgen deprivation for oligometastases in prostate cancer. Int J Radiat Oncol Biol Phys. 2021;111(3S):S59.

    Article  Google Scholar 

  52. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–8.

    Article  PubMed  PubMed Central  Google Scholar 

  53. G.A.P consortium, De Bruycker A, Tran PT, Achtman AH, Ost P. Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. World J Urol. 2021;39(2):317–26.

    Article  Google Scholar 

  54. Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. Eur Urol. 2021;80(3):275–9.

    Article  CAS  PubMed  Google Scholar 

  55. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74.

    Article  CAS  PubMed  Google Scholar 

  56. Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21(41):11767–76.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer. 2021;124(3):587–94.

    Article  CAS  PubMed  Google Scholar 

  58. Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O’Neil BH, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(18 suppl):LBA3–LBA3.

    Article  Google Scholar 

  59. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31(1):19–31.

    Article  PubMed  Google Scholar 

  60. Ramos E, Martinez L, Gamez C, Torras J, Valls C, Rafecas A, et al. Use of PET-CT in pre-surgical staging of colorectal cancer hepatic metastases. Cir Esp. 2008;84(2):71–7.

    Article  PubMed  Google Scholar 

  61. Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2015;42(1):152–63.

    Article  CAS  PubMed  Google Scholar 

  62. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.

    Article  PubMed  Google Scholar 

  63. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27(9):1746–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018;9(1):1793.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18.

    Article  CAS  PubMed  Google Scholar 

  66. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11(8):1057–77.

    Article  PubMed  Google Scholar 

  68. Vera R, Gonzalez-Flores E, Rubio C, Urbano J, Valero Camps M, Ciampi-Dopazo JJ, et al. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM. Clin Transl Oncol. 2020;22(5):647–62.

    Article  CAS  PubMed  Google Scholar 

  69. Allard MA, Adam R, Giuliante F, Lapointe R, Hubert C, Ijzermans JNM, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017;117(5):604–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Omichi K, Shindoh J, Cloyd JM, Mizuno T, Chun YS, Conrad C, et al. Liver resection is justified for patients with bilateral multiple colorectal liver metastases: a propensity-score-matched analysis. Eur J Surg Oncol. 2018;44(1):122–9.

    Article  PubMed  Google Scholar 

  71. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Adam R, de Haas RJ, Wicherts DA, Vibert E, Salloum C, Azoulay D, et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg. 2011;253(2):349–59.

    Article  PubMed  Google Scholar 

  73. Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, et al. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 2014;50(10):1747–57.

    Article  PubMed  Google Scholar 

  74. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.

    Article  CAS  PubMed  Google Scholar 

  75. Liu W, Zhou JG, Sun Y, Zhang L, Xing BC. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis. Oncotarget. 2016;7(24):37277–87.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9):15.

    Article  Google Scholar 

  77. Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol. 2008;19(5):712–7.

    Article  PubMed  Google Scholar 

  78. Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36.

    Article  PubMed  Google Scholar 

  79. Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81(1):25–34.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958–68.

    Article  PubMed  Google Scholar 

  81. Luo M, Chen SL, Chen J, Yan H, Qiu Z, Chen G, et al. Resection vs. ablation for lesions characterized as resectable-ablative within the colorectal liver oligometastases criteria: a propensity score matching from retrospective study. PeerJ. 2020;8:e8398.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Delpla A, de Baere T, Varin E, Deschamps F, Roux C, Tselikas L. Role of thermal ablation in colorectal cancer lung metastases. Cancers (Basel). 2021;13(4):908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. (NCNN), N.C.C.N. NCNN clinical practice guidelines in oncology-Colon Cancer. V3. 2021. 2021; Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

  84. Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) patient registry. Radiat Oncol. 2018;13(1):26.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Kobiela J, Spychalski P, Marvaso G, Ciardo D, Dell’Acqua V, Kraja F, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol. 2018;129:91–101.

    Article  CAS  PubMed  Google Scholar 

  86. Kim M, Son SH, Won YK, Kay CS. Stereotactic ablative radiotherapy for oligometastatic disease in liver. Biomed Res Int. 2014;2014: 340478.

    PubMed  PubMed Central  Google Scholar 

  87. Cathail SMO, Smith T, Owens R, Zeniou A, Tsang Y, Holyoake D, et al. Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiother Oncol. 2020. https://doi.org/10.1016/j.radonc.2020.08.012.

    Article  Google Scholar 

  88. Greco C, Pares O, Pimentel N, Moser E, Louro V, Morales X, et al. Spinal metastases: from conventional fractionated radiotherapy to single-dose SBRT. Report Pract Oncolo Radiother. 2015;20(6):454–63.

    Article  Google Scholar 

  89. Soltys SG, Grimm J, Milano MT, Xue J, Sahgal A, Yorke E, et al. Stereotactic body radiation therapy for spinal metastases: tumor control probability analyses and recommended reporting standards. Int J Radiat Oncol Biol Phys. 2021;110(1):112–23.

    Article  PubMed  Google Scholar 

  90. Ito K, Nakajima Y, Onoe T, Ogawa H, Harada H, Saito M, et al. Phase 2 clinical trial of stereotactic body radiation therapy for painful nonspine bone metastases. Pract Radiat Oncol. 2021;11(2):e139–45.

    Article  PubMed  Google Scholar 

  91. Zeng KL, Tseng CL, Soliman H, Weiss Y, Sahgal A, Myrehaug S. Stereotactic Body radiotherapy (SBRT) for oligometastatic spine metastases: an overview. Front Oncol. 2019;9:337.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Wilson DD, Alonso CE, Sim AJ, Peck T, Handsfield LL, Chen Q, et al. STAT RT: a prospective pilot clinical trial of scan-plan-QA-treat stereotactic body radiation therapy for painful osseous metastases. Ann Palliat Med. 2019;8(3):221–30.

    Article  PubMed  Google Scholar 

  93. Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950–8.

    Article  PubMed  Google Scholar 

  94. Stintzing S, Grothe A, Hendrich S, Hoffmann RT, Heinemann V, Rentsch M, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–7.

    Article  PubMed  Google Scholar 

  95. Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol. 2020;145:63–70.

    Article  PubMed  Google Scholar 

  96. Mutsaers A, Greenspoon J, Walker-Dilks C, Swaminath A. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiat Oncol. 2017;12(1):110.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Jin H, Chalkidou A, Hawkins M, Summers J, Eddy S, Peacock JL, et al. Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: metastatic liver cancer and hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2021;33(3):e143–54.

    Article  CAS  PubMed  Google Scholar 

  98. Kumar A, Straka C, Courtney PT, Vitzthum L, Riviere P, Murphy JD. Cost-effectiveness analysis of stereotactic ablative radiation therapy in patients with oligometastatic cancer. Int J Radiat Oncol Biol Phys. 2021;109(5):1185–94.

    Article  PubMed  Google Scholar 

  99. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.

    Article  CAS  PubMed  Google Scholar 

  101. Oxenberg J, Papenfuss W, Esemuede I, Attwood K, Simunovic M, Kuvshinoff B, et al. Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol. 2015;22(5):1533–9.

    Article  PubMed  Google Scholar 

  102. Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–62.

    Article  CAS  PubMed  Google Scholar 

  103. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.

    Article  CAS  PubMed  Google Scholar 

  104. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr Álvaro Rodríguez-Lescure (former president of SEOM) and Dr Jorge Contreras Martínez (former president of SEOR) who facilitated the organization of the “I Jornada Virtual de Consenso SEOM-SEOR sobre el Abordaje Multidisciplinar de la Enfermedad Oligometastásica”, and Dr Juan de la Haba Rodríguez. (SEOM), Dr. Manel Algara López (SEOR), Dr Ana Fernández Montes (SEOM), and Dr Carmen Rubio Rodríguez (SEOR) for their valuable contribution as moderators of the sessions. The authors would like to thank Dr Susana Cañón-Sánchez (from Statistics Consulting S.L., Valencia, Spain) for providing scientific support and medical writing services.

Funding

This work was funded by SEOR and SEOM.

Author information

Authors and Affiliations

  1. Radiation Oncology Department, Hospital Universitari i Politècnic La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, Spain

    Antonio José Conde-Moreno

  2. Medical Oncology Department, Universitario Puerta de Hierro Majadahonda, Madrid, Spain

    Aránzazu González-del-Alba

  3. Radiation Oncology Department, Hospital Ramón y Cajal, Madrid, Spain

    Fernando López-Campos

  4. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Carlos López López

  5. Radiation Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain

    Ovidio Hernando Requejo & Ángel Montero-Luis

  6. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain

    Javier de Castro Carpeño

  7. Department of Radiation Oncology, ASCIRES Grupo Biomédico, Valencia, Spain

    Rodolfo Chicas-Sett

  8. Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, La Coruña, Spain

    Laura de Paz Arias

  9. Radiation Oncology, Hospital Ruber Internacional, Madrid, Spain

    Aurora Rodríguez Pérez

  10. Medical Oncology, Hospital Universitario del Vall d’Hebron, Barcelona, Spain

    Enriqueta Felip Font

  11. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    José Ángel Arranz Arija

Authors
  1. Antonio José Conde-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aránzazu González-del-Alba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando López-Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos López López
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ovidio Hernando Requejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Javier de Castro Carpeño
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rodolfo Chicas-Sett
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laura de Paz Arias
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ángel Montero-Luis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aurora Rodríguez Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Enriqueta Felip Font
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. José Ángel Arranz Arija
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors were involved in the conception of this work, drafting and/or revising the manuscript, and approved the final version.

Corresponding author

Correspondence to Antonio José Conde-Moreno.

Ethics declarations

Conflict of interest

JAA has received speaker honoraria from Astellas Pharma, Pfizer and Bristol-Myers Squibb, and consultancy fees from Pfizer, Astellas Pharma, Janssen-Cilag, MSD Oncology, BMS, Merck, AstraZeneca, Bayer, Eisai and Novartis. AGdA, has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD and Ipsen; and honoraria for speaking engagements, membership of advisory boards and continuing medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Merck, Eusa Pharma, Eisai and Astra Zeneca. JdCC has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Hoffmann- La Roche and Takeda; RCh-S, has received honoraria for speaking engagements from Astrazeneca, Fresenius-Kabi, Grunenthal and Adventia Pharma; and declares financial relationship with Fresenius-Kabi and Adventia Pharma. EFF has received consultancy honoraria from Amgen, Astrazeneca, Bayer, Bristol Myers Squibb, Daiichi Dankyo, Eli Lilly, F. Hoffmann-La Roche, Glaxo Smith Kline, Janssen, Merck Sharp and Dome, Merck Serono, Novartis, Peptomyc, Pfizer, Sanofi and Takeda and speaker honoraria from Amgen, Astrazeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Janssen, Medscape, Merck Sharp and Dome, Peervoice, Pfizer, Medical Trends, Merck Serono, Sanofi, Takeda and TouchOncology. All other authors declare no relevant financial or non-financial interests to disclose.

Informed consent

For this type of study formal consent is not required.

Ethical approval

This article dose not contain any studies with human participants or animal performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Conde-Moreno, A.J., González-del-Alba, A., López-Campos, F. et al. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer. Clin Transl Oncol 25, 897–911 (2023). https://doi.org/10.1007/s12094-022-03019-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-03019-y

Keywords

Search

Navigation